Engineering collismycin biosynthesis enables potent acetylcholinesterase inhibitors
Jiyuan Yang1, Yanqing Li2, Jingjing Li1
1State Key Laboratory of Discovery and Utilization of Functional Components in Traditional Chinese Medicine, School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, Jinan 250012, P. R. China. fangrunping@sdu.edu.cn.
Abstract:
Collismycins suffer from limited structural diversity that restricts bioactivity exploration. Herein, we develop a bio-chemo-relay strategy combining biosynthetic engineering and chemical diversification to construct diverse collismycin analogues, affording a potent acetylcholinesterase inhibitor 4h with superior activity to galantamine.
Related Concept Videos
Indirect-Acting Cholinergic Agonists: Mechanism of Action
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex, leading to...
Inhibitors of Bacterial Protein Synthesis
Indirect-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...
Direct-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship
The direct-acting...
Anticholinesterase Agents: Poisoning and Treatment
Irreversible agents form a strong bond with the cholinesterase enzyme, making it inactive. The breakdown of the phosphorylated enzyme is slower than the...
Direct-Acting Cholinergic Agonists: Pharmacokinetics


